<?xml version="1.0" encoding="UTF-8"?>
<!DOCTYPE article
  PUBLIC "-//NLM//DTD Journal Publishing DTD v2.3 20070202//EN" "journalpublishing.dtd">
<article xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink" article-type="review-article">
<front>
<journal-meta>
<journal-id journal-id-type="publisher-id">JIC</journal-id>
<journal-id journal-id-type="hwp">spjic</journal-id>
<journal-id journal-id-type="nlm-ta">J Intensive Care Med</journal-id>
<journal-title>Journal of Intensive Care Medicine</journal-title>
<issn pub-type="ppub">0885-0666</issn>
<issn pub-type="epub">1525-1489</issn>
<publisher>
<publisher-name>SAGE Publications</publisher-name>
<publisher-loc>Sage CA: Los Angeles, CA</publisher-loc>
</publisher>
</journal-meta>
<article-meta>
<article-id pub-id-type="doi">10.1177/0885066611402463</article-id>
<article-id pub-id-type="publisher-id">10.1177_0885066611402463</article-id>
<article-categories>
<subj-group subj-group-type="heading">
<subject>Analytic Reviews</subject>
</subj-group>
</article-categories>
<title-group>
<article-title>Fever in the Critically Ill</article-title>
<subtitle>A Review of Epidemiology, Immunology, and Management</subtitle>
</title-group>
<contrib-group>
<contrib contrib-type="author" corresp="yes">
<name>
<surname>Niven</surname>
<given-names>Daniel J.</given-names>
</name>
<degrees>MD, FRCPC</degrees>
<xref ref-type="aff" rid="aff1-0885066611402463">1</xref>
<xref ref-type="corresp" rid="corresp1-0885066611402463"/>
</contrib>
<contrib contrib-type="author">
<name>
<surname>Léger</surname>
<given-names>Caroline</given-names>
</name>
<degrees>PhD</degrees>
<xref ref-type="aff" rid="aff2-0885066611402463">2</xref>
</contrib>
<contrib contrib-type="author">
<name>
<surname>Stelfox</surname>
<given-names>Henry T.</given-names>
</name>
<degrees>MD, PhD, FRCPC</degrees>
<xref ref-type="aff" rid="aff1-0885066611402463">1</xref>
<xref ref-type="aff" rid="aff3-0885066611402463">3</xref>
<xref ref-type="aff" rid="aff4-0885066611402463">4</xref>
</contrib>
<contrib contrib-type="author">
<name>
<surname>Laupland</surname>
<given-names>Kevin B.</given-names>
</name>
<degrees>MD, MSc, FRCPC</degrees>
<xref ref-type="aff" rid="aff1-0885066611402463">1</xref>
<xref ref-type="aff" rid="aff3-0885066611402463">3</xref>
<xref ref-type="aff" rid="aff4-0885066611402463">4</xref>
</contrib>
</contrib-group>
<aff id="aff1-0885066611402463">
<label>1</label>Department of Critical Care Medicine, University of Calgary and Alberta Health Services, Calgary, Alberta, Canada</aff>
<aff id="aff2-0885066611402463">
<label>2</label>Department of Physiology and Pharmacology, University of Calgary and Alberta Health Services, Calgary, Alberta, Canada</aff>
<aff id="aff3-0885066611402463">
<label>3</label>Department of Medicine, University of Calgary and Alberta Health Services, Calgary, Alberta, Canada</aff>
<aff id="aff4-0885066611402463">
<label>4</label>Department of Community Health Sciences, University of Calgary and Alberta Health Services, Calgary, Alberta, Canada</aff>
<author-notes>
<corresp id="corresp1-0885066611402463">Daniel J. Niven, Critical Care Medicine, Foothills Medical Center, 1403-29th St NW, Calgary Alberta, Canada T2N 2T9 Email: <email>Daniel.niven@albertahealthservices.ca</email>
</corresp>
</author-notes>
<pub-date pub-type="epub-ppub">
<month>9</month>
<year>2012</year>
</pub-date>
<volume>27</volume>
<issue>5</issue>
<fpage>290</fpage>
<lpage>297</lpage>
<permissions>
<copyright-statement>© The Author(s) 2012</copyright-statement>
<copyright-year>2012</copyright-year>
<copyright-holder content-type="sage">SAGE Publications</copyright-holder>
</permissions>
<abstract>
<p>Fever is common among patients admitted to intensive care units (ICUs). In spite of the frequency of its occurrence, the biological mechanisms regulating the initiation and progression of fever are poorly understood. In addition, there are few large studies reporting on the epidemiology and etiology of fever in general medical and surgical ICU patients. Current evidence suggests that the development of high fever by patients admitted to ICUs with a medical admission diagnosis is associated with an increased risk of death. The decision to treat fever should therefore be obvious, but several lines of evidence argue against temperature-lowering strategies. Furthermore, the use of different temperature control strategies in febrile patients without acute brain injury or acute myocardial infarction is guided by a paucity of randomized clinical trials and by a lack of understanding of the biology of the induction and control of fever. As such, a review of the epidemiology, molecular mechanisms, and immunology of fever as well as the evidence behind management of fever in the critically ill is pertinent to all critical care practitioners.</p>
</abstract>
<kwd-group>
<kwd>fever</kwd>
<kwd>ICU</kwd>
<kwd>inflammatory mediators</kwd>
<kwd>heat shock</kwd>
<kwd>antipyretic</kwd>
</kwd-group>
<custom-meta-wrap>
<custom-meta>
<meta-name>cover-date</meta-name>
<meta-value>September/October 2012</meta-value>
</custom-meta>
</custom-meta-wrap>
</article-meta>
</front>
<body>
<sec id="section1-0885066611402463">
<title>Introduction</title>
<p>Fever, an adaptive response to physiologic stress, is one of the most commonly observed abnormal signs in patients with critical illness, occurring in almost 50% of patients admitted to intensive care units (ICUs).<sup><xref ref-type="bibr" rid="bibr1-0885066611402463">1</xref><xref ref-type="bibr" rid="bibr2-0885066611402463"/>–<xref ref-type="bibr" rid="bibr3-0885066611402463">3</xref></sup> In addition to being common, fever has also been shown to be independently associated with mortality in patients admitted to ICUs.<sup><xref ref-type="bibr" rid="bibr1-0885066611402463">1</xref>,<xref ref-type="bibr" rid="bibr4-0885066611402463">4</xref></sup> In spite of this, there is a lack of robust data to guide fever management. This frequently leaves the decision to treat elevated body temperature at the discretion of the bedside nurse.<sup><xref ref-type="bibr" rid="bibr5-0885066611402463">5</xref></sup> This decision is further complicated by the contradictory nature of the current available molecular data regarding the initiation and progression of fever, which leads to difficulties in knowing which pathways may be involved and therefore which temperature-lowering strategy should be used.</p>
<p>As it is unclear how to approach fever in the general ICU patient without acute brain injury (neurologically intact) or acute myocardial infarction, this article will review the epidemiology, and immunology of fever as well as the evidence behind the management of fever in neurologically intact ICU patients.</p>
</sec>
<sec id="section2-0885066611402463">
<title>Search Strategy</title>
<p>A semistructured literature review was conducted using PubMed from 1966 to July 1, 2010, with the goals of identifying articles that focused on: (1) the epidemiology of fever and its management in the ICU and (2) molecular mechanisms of fever. Search terms included: (1) fever or hyperthermia and ICU and (2) fever, mechanism and cytokine, or fever and heat shock. Abstracts were screened for relevance and appropriate full-length articles were retrieved for appraisal. The bibliographies of significant articles were also screened for other pertinent articles.</p>
</sec>
<sec id="section3-0885066611402463">
<title>Temperature Measurement and Fever Etiology</title>
<p>A core body temperature of ≥38.3°C is generally accepted to represent fever.<sup><xref ref-type="bibr" rid="bibr3-0885066611402463">3</xref></sup> Fever can be further classified as high fever or prolonged fever, which are usually defined at a temperature of ≥39.5°C or any fever lasting for ≥5 days, respectively.<sup><xref ref-type="bibr" rid="bibr4-0885066611402463">4</xref>,<xref ref-type="bibr" rid="bibr6-0885066611402463">6</xref>,<xref ref-type="bibr" rid="bibr7-0885066611402463">7</xref></sup> Although temperature is a fundamental vital sign, little is known about how and when different technologies are employed to measure temperature in clinical practice. The gold standard for measuring core temperature is the thermistor on a pulmonary-artery catheter (PAC). Similarly, accurate temperature recordings can be obtained from urinary bladder catheter thermistors, esophageal probes, and rectal thermometers.<sup><xref ref-type="bibr" rid="bibr8-0885066611402463">8</xref></sup> Unfortunately, these methods of temperature measurement are generally too expensive to use on all critically ill patients. Therefore, the temperature of many ICU patients is commonly assessed using more cost-effective, less invasive, albeit less accurate devices such as the infrared tympanic membrane and temporal artery thermometers. Given the potential inaccuracy of tympanic membrane and temporal artery thermometers, data obtained from these devices must be interpreted with caution.<sup><xref ref-type="bibr" rid="bibr9-0885066611402463">9</xref></sup>
</p>
<p>Elevated body temperatures in the critically ill can be classified into 3 major categories: (1) the hyperthermia syndromes, (2) infectious fever, and (3) noninfectious fever. The hyperthermia syndromes include heatstroke, neuroleptic malignant syndrome, malignant hyperthermia, severe thyrotoxicosis, pheochromocytoma, and adrenal crisis.<sup><xref ref-type="bibr" rid="bibr10-0885066611402463">10</xref><xref ref-type="bibr" rid="bibr11-0885066611402463"/>–<xref ref-type="bibr" rid="bibr12-0885066611402463">12</xref></sup> These syndromes are characterized by aberrant thermoregulatory homeostasis via mechanisms that differ from fever due to infectious and noninfectious causes and will not be discussed further in this article.</p>
<p>Infectious etiologies of fever can be divided into 5 main categories: bacterial, viral, fungal, parasitic, and protozoal. Bacteria are the most common etiologic pathogens and are typically associated with positive cultures. The most common sites of infection in critically ill patients include the lower respiratory tract, urinary tract, primary bloodstream, sinuses, skin/soft tissue, and intra-abdominal.<sup><xref ref-type="bibr" rid="bibr13-0885066611402463">13</xref><xref ref-type="bibr" rid="bibr14-0885066611402463"/><xref ref-type="bibr" rid="bibr15-0885066611402463"/>–<xref ref-type="bibr" rid="bibr16-0885066611402463">16</xref></sup> Not all fevers are infectious in etiology. Noninfectious causes of fever are common and include transfusion reactions, drug hypersensitivity reactions, venous thromboembolic disease, deep body site hematomas, myocardial infarction, pancreatitis, acalculous cholecystitis, and neurogenic fever such as that which commonly occurs following subarachnoid hemorrhage.</p>
</sec>
<sec id="section4-0885066611402463">
<title>Mechanism of Fever and Related Immunology</title>
<sec id="section5-0885066611402463">
<title>Fever Mechanism</title>
<p>The production of fever involves a complex series of reactions between exogenous and endogenous pyrogens. Although the mechanism of fever induction is complex, knowledge of this mechanism is important as it will help to guide clinical decisions regarding the management of patients with pyrexia. The classical view on the induction of infectious fever is derived from a lipopolysaccharide (LPS) model of Gram-negative bacterial sepsis. In this model, the exogenous pyrogen (LPS) activates mononuclear phagocytic cells to produce endogenous pyrogenic cytokines such as those listed in <xref ref-type="table" rid="table1-0885066611402463">Table 1</xref>
.<sup><xref ref-type="bibr" rid="bibr17-0885066611402463">17</xref></sup> These molecules are transported via the blood to circumventricular organs where they cross the blood-brain barrier (BBB) to enter the preoptic nucleus of the hypothalamus and promote the transformation of arachadonic acid to prostaglandin-E<sub>2</sub> (PGE<sub>2</sub>) via the cyclooxygenase (COX) enzyme COX-2.<sup><xref ref-type="bibr" rid="bibr17-0885066611402463">17</xref></sup> Prostaglandin-E<sub>2</sub> then leads to a depression in the firing of the warm-sensitive neurons and an increase in core body temperature.<sup><xref ref-type="bibr" rid="bibr18-0885066611402463">18</xref></sup>
</p>
<table-wrap id="table1-0885066611402463" position="float">
<label>Table 1.</label>
<caption>
<p>Endogenous Pyrogenic and Antipyretic Mediators</p>
</caption>
<graphic alternate-form-of="table1-0885066611402463" xlink:href="10.1177_0885066611402463-table1.tif"/>
<table>
<thead>
<tr>
<th>Mediator</th>
<th>Role in Pyrexia</th>
<th>Reference</th>
</tr>
</thead>
<tbody>
<tr>
<td>IL-1</td>
<td>The most potent endogenous pyrogen</td>
<td>Dinarello<sup><xref ref-type="bibr" rid="bibr57-0885066611402463">57</xref></sup>
</td>
</tr>
<tr>
<td>TNF-α</td>
<td>Endogenous pyrogen and ubiquitous mediator of inflammation</td>
<td>Dinarello<sup><xref ref-type="bibr" rid="bibr58-0885066611402463">58</xref></sup>
</td>
</tr>
<tr>
<td>IL-6</td>
<td>Endogenous pyrogen</td>
<td>Chai et al<sup><xref ref-type="bibr" rid="bibr59-0885066611402463">59</xref></sup>
</td>
</tr>
<tr>
<td>NF-κB</td>
<td>Transcription factor controlling expression of endogenous pyrogens</td>
<td>De Bosscher et al<sup><xref ref-type="bibr" rid="bibr30-0885066611402463">30</xref></sup>
</td>
</tr>
<tr>
<td>AP-1</td>
<td>Transcription factor controlling expression of endogenous pyrogens</td>
<td>De Bosscher et al<sup><xref ref-type="bibr" rid="bibr30-0885066611402463">30</xref></sup>
</td>
</tr>
<tr>
<td>IL-1 RA</td>
<td>Endogenous antipyretic cytokine</td>
<td>Luheshi et al<sup><xref ref-type="bibr" rid="bibr31-0885066611402463">31</xref></sup>
</td>
</tr>
<tr>
<td>IL-10</td>
<td>Endogenous antipyretic cytokine</td>
<td>Cartmell et al<sup><xref ref-type="bibr" rid="bibr32-0885066611402463">32</xref></sup>
</td>
</tr>
<tr>
<td>TNF-α-BP</td>
<td>Endogenous antipyretic cytokine</td>
<td>Roth et al<sup><xref ref-type="bibr" rid="bibr33-0885066611402463">33</xref></sup>
</td>
</tr>
</tbody>
</table>
<table-wrap-foot>
<fn id="table-fn1-0885066611402463">
<p>Abbreviations: IL-1, interleukin-1; IL-6, interleukin-6; IL-10, interleukin-10; IL-1 RA, interleukin-1 receptor antagonist; TNF-α, tumour necrosis factor-α; NF-κB, nuclear factor-κB; AP-1, activator protein-1; TNF-α-BP, tumour necrosis factor-α binding protein.</p>
</fn>
</table-wrap-foot>
</table-wrap>
<p>Over the last 10 years, this mechanism has been challenged by a number of inconsistencies in its foundation. Animal studies have found that cytokines are not detected in plasma until approximately 30 minutes following LPS injection, whereas an increase in core temperature occurs within 10 minutes of the same injection.<sup><xref ref-type="bibr" rid="bibr19-0885066611402463">19</xref>,<xref ref-type="bibr" rid="bibr20-0885066611402463">20</xref></sup> The elevation of body temperature also occurs before the increase in expression of the hypothalamic COX enzymes responsible for PGE<sub>2</sub> production in response to exogenous pyrogens.<sup><xref ref-type="bibr" rid="bibr21-0885066611402463">21</xref></sup> Finally, given the lipophilicity and tight junctions between endothelial cells that make up the BBB, it is unlikely that the hydrophilic cytokine molecules are able to enter the preoptic area of the hypothalamus by passively crossing the BBB. Recent studies have proposed a new mechanism for the induction of an infectious fever.<sup><xref ref-type="bibr" rid="bibr22-0885066611402463">22</xref></sup> In this mechanism, LPS travels to the Kupffer cell of the liver,<sup><xref ref-type="bibr" rid="bibr23-0885066611402463">23</xref></sup> where the endogenous pyrogenic signal begins with production of the complement component C5a.<sup><xref ref-type="bibr" rid="bibr24-0885066611402463">24</xref></sup> Complement component C5a promotes the release of PGE<sub>2</sub> from the Kupffer cell,<sup><xref ref-type="bibr" rid="bibr23-0885066611402463">23</xref></sup> which stimulates local vagal afferents that transmit the message via the vagus nerve to the nucleus tractus solitarius in the brainstem.<sup><xref ref-type="bibr" rid="bibr22-0885066611402463">22</xref>,<xref ref-type="bibr" rid="bibr25-0885066611402463">25</xref></sup> The signal then travels to the hypothalamus and triggers both an early and a delayed rise in temperature (the 2 phases of infectious fever induction). The early temperature rise is a result of the depression of the firing of warm-sensitive neurons via an α<sub>1</sub>-adreno receptor (AR), PGE-independent pathway.<sup><xref ref-type="bibr" rid="bibr26-0885066611402463">26</xref></sup> Clinically, this correlates with chills and rigors.<sup><xref ref-type="bibr" rid="bibr27-0885066611402463">27</xref></sup> The delayed temperature rise starts with an interaction between norepinephrine and an α<sub>2</sub>-AR that results in an increase in PGE<sub>2</sub> production via COX-2.<sup><xref ref-type="bibr" rid="bibr26-0885066611402463">26</xref></sup> This is associated with a more prolonged rise in core temperature than that of the PGE-independent rapid pathway and is responsible for the persistence of fever in the face of an infectious stimulus. This delayed pathway is also the likely site of action of antipyretics such as clonidine and acetaminophen; however, the effects of these drugs on most of the aforementioned mediators of infectious fever are not clearly understood.<sup><xref ref-type="bibr" rid="bibr22-0885066611402463">22</xref>,<xref ref-type="bibr" rid="bibr26-0885066611402463">26</xref>,<xref ref-type="bibr" rid="bibr28-0885066611402463">28</xref></sup> The effects of external cooling on the mediators of the rapid and delayed phases of an infectious fever are also currently unclear. Knowledge of the biologic consequences of fever management is important because excessively elevated temperatures are associated with adverse cellular effects yet strategies that lower temperature may impair the ability of the host to clear an infection.</p>
<p>Given that excessively elevated temperatures are associated with adverse effects, the magnitude and duration of fever are under the control of endogenous antipyretics. These include glucocorticoids, neuropeptides, and cytokines.<sup><xref ref-type="bibr" rid="bibr29-0885066611402463">29</xref></sup> Glucocorticoids control the expression of pyrogenic cytokines by acting on the transcription factors nuclear factor-κB (NF-κB), activator protein-1 (AP-1), and their downstream products IL-1β, IL-6, and TNF-α.<sup><xref ref-type="bibr" rid="bibr30-0885066611402463">30</xref></sup> In addition, fever is regulated by the production of several antipyretic cytokines, the most studied of which include the IL-1 receptor antagonist (IL-1 RA),<sup><xref ref-type="bibr" rid="bibr31-0885066611402463">31</xref></sup> IL-10,<sup><xref ref-type="bibr" rid="bibr32-0885066611402463">32</xref></sup> and TNF-α-binding protein (TNF-α-BP).<sup><xref ref-type="bibr" rid="bibr33-0885066611402463">33</xref></sup> The other main mechanism preventing an overwhelming febrile response is the shedding of important receptors, such as IL-6R and TNF-RI, thus blunting the further activation of the target cells by these pyrogenic cytokines.<sup><xref ref-type="bibr" rid="bibr34-0885066611402463">34</xref>,<xref ref-type="bibr" rid="bibr35-0885066611402463">35</xref></sup> The current literature does not provide a clear picture on the timing of the interactions between the pyrogenic and antipyretic pathways. It is also unclear whether the induction of infectious and noninfectious fever follows a similar molecular route.</p>
</sec>
<sec id="section6-0885066611402463">
<title>Heat Shock Proteins</title>
<p>Endogenous antipyretic mediators do not represent the sole mechanism by which cells are protected against the effects of pyrexia. This is the role of the heat shock response (HSR) that is mediated by the heat shock proteins (HSPs). The HSR is an evolutionarily conserved mechanism in which cells overexpress the HSPs in response to a number of stressful stimuli (eg elevated temperature, hypoxia, and chemical toxins) that cause denaturation of vital proteins. Heat shock proteins interact with the denatured proteins to preserve them, assist in their proper refolding, or promote their elimination from the cell.<sup><xref ref-type="bibr" rid="bibr36-0885066611402463">36</xref></sup>
</p>
<p>The HSPs are subdivided based on their molecular weight, with HSP60 and HSP70 being the most frequently studied in relation to fever. The role of HSP70 as a cytoprotective agent in the cell’s response to elevated body temperatures is supported by several lines of evidence. The inducible form of HSP70 is detected in increased quantity in the brain tissue of rats in response to pyrexia.<sup><xref ref-type="bibr" rid="bibr37-0885066611402463">37</xref>,<xref ref-type="bibr" rid="bibr38-0885066611402463">38</xref></sup> Animal studies have also shown that chronic overexpression of HSP70 via exposure to hyperthermic conditions confers protection to the tissues during subsequent extreme hyperthermia exposure.<sup><xref ref-type="bibr" rid="bibr38-0885066611402463">38</xref></sup> Studies by Ryan<sup><xref ref-type="bibr" rid="bibr39-0885066611402463">39</xref></sup> and Hotchkiss<sup><xref ref-type="bibr" rid="bibr40-0885066611402463">40</xref></sup> found a decreased mortality rate in rats preconditioned to overexpress HSP70 compared to control animals in response to lethal doses of endotoxin. Subsequent in vitro study has shown that this may be due to the ability of HSP70 to signal a decrease in the production of proinflammatory mediators, particularly pro-IL-1β and NF-κB.<sup><xref ref-type="bibr" rid="bibr41-0885066611402463">41</xref>,<xref ref-type="bibr" rid="bibr42-0885066611402463">42</xref></sup>
</p>
<p>The potential effects of pharmacologic and nonpharmacologic antipyresis on the magnitude and duration of the HSR bring clinical relevance to this basic science discussion. Only 1 in vivo sheep study has demonstrated a decrease in HSP70 levels when the animals were treated with acetaminophen and external cooling following an experimental peritonitis.<sup><xref ref-type="bibr" rid="bibr43-0885066611402463">43</xref></sup> This study should be interpreted with caution since the authors have not given antibiotics to the animals, which is not representative of clinical practice. This study nonetheless leads us to believe that clinical strategies that lower the temperature of patients with severe infections may suppress the HSR and thus preclude the potential positive effects of this evolutionarily preserved mechanism. To date, there is no clinical data to support or refute this argument.</p>
</sec>
</sec>
<sec id="section7-0885066611402463">
<title>Epidemiology of Fever in the Critically Ill</title>
<p>There are a limited number of studies reporting on the epidemiology of fever in general medical and surgical ICU patients.<sup><xref ref-type="bibr" rid="bibr1-0885066611402463">1</xref>,<xref ref-type="bibr" rid="bibr4-0885066611402463">4</xref>,<xref ref-type="bibr" rid="bibr6-0885066611402463">6</xref>,<xref ref-type="bibr" rid="bibr44-0885066611402463">44</xref></sup> A brief summary of these studies is provided in <xref ref-type="table" rid="table2-0885066611402463">Table 2</xref>
. Circiumaru et al prospectively studied fever in 93 patients over a 4-month period and found fever among 70% of admissions.<sup><xref ref-type="bibr" rid="bibr6-0885066611402463">6</xref></sup> There were similar proportions of infectious and noninfectious etiologies. The presence of prolonged fever was associated with increased mortality (62.5% vs 29.6% for prolonged fever and fever, respectively, <italic>P</italic> &lt; .0001); however, this is not adjusted for illness severity, etiology, or other potential confounding factors.</p>
<table-wrap id="table2-0885066611402463" position="float">
<label>Table 2.</label>
<caption>
<p>Studies That Address the Epidemiology of Fever in General Medical and Surgical Patients Admitted to ICU</p>
</caption>
<graphic alternate-form-of="table2-0885066611402463" xlink:href="10.1177_0885066611402463-table2.tif"/>
<table>
<thead>
<tr>
<th>Reference</th>
<th>Setting</th>
<th>Number of Patients</th>
<th>Fever Definition (°C)</th>
<th>Fever Incidence (%)</th>
<th>Infectious Fever Etiology</th>
<th>Outcomes</th>
</tr>
</thead>
<tbody>
<tr>
<td>Circiumaru et al.<sup><xref ref-type="bibr" rid="bibr6-0885066611402463">6</xref></sup>
</td>
<td>General ICU</td>
<td>93</td>
<td>≥38.4</td>
<td>70</td>
<td>53%</td>
<td>Increased mortality with prolonged fever (62.5% vs 29.6%)<sup><xref ref-type="table-fn" rid="table-fn4-0885066611402463">b</xref></sup>
</td>
</tr>
<tr>
<td>Peres Bota et al<sup><xref ref-type="bibr" rid="bibr44-0885066611402463">44</xref></sup>
</td>
<td>General ICU</td>
<td>493</td>
<td>≥38.3</td>
<td>28.2</td>
<td>55%</td>
<td>Increased mortality among febrile patients (35.3% vs 10.3%)<sup><xref ref-type="table-fn" rid="table-fn4-0885066611402463">b</xref></sup>
</td>
</tr>
<tr>
<td>Barie et al.<sup><xref ref-type="bibr" rid="bibr4-0885066611402463">4</xref></sup>
</td>
<td>Surgical ICU</td>
<td>2,419</td>
<td>≥38.2</td>
<td>26</td>
<td>46%</td>
<td>Increased mortality among febrile patients (26.5% vs 6.5%)<sup><xref ref-type="table-fn" rid="table-fn4-0885066611402463">b</xref></sup>
</td>
</tr>
<tr>
<td>Laupland et al<sup><xref ref-type="bibr" rid="bibr1-0885066611402463">1</xref></sup>
</td>
<td>3 general ICUs; 1 CVICU</td>
<td>20 466</td>
<td>≥38.3</td>
<td>44<sup><xref ref-type="table-fn" rid="table-fn3-0885066611402463">a</xref></sup>
</td>
<td>34% Culture positive</td>
<td>OR (death) 1.91 for medical patients who acquire high fever in ICU</td>
</tr>
</tbody>
</table>
<table-wrap-foot>
<fn id="table-fn2-0885066611402463">
<p>Abbreviations: CVICU, cardiovascular surgical intensive care unit; OR, odds ratio.</p></fn>
<fn id="table-fn3-0885066611402463">
<p>
<sup>a</sup> Given as cumulative incidence of fever.</p></fn>
<fn id="table-fn4-0885066611402463">
<p>
<sup>b</sup>
<italic>P</italic> &lt; .01.</p>
</fn>
</table-wrap-foot>
</table-wrap>
<p>Peres Bota et al prospectively studied fever among 493 adult patients admitted to their tertiary care ICU.<sup><xref ref-type="bibr" rid="bibr44-0885066611402463">44</xref></sup> Fever occurred in 139 (28.2%) patients, was commonly present at ICU admission (76.3%), and was infectious in origin in 55% of these patients. The most common noninfectious cause of fever was postoperative fever (19%). These authors showed that febrile patients had significantly increased mortality compared to patients with normothermia (35.3% vs 10.3%, <italic>P</italic> &lt; .01); however, these data are also not adjusted for potential confounders.</p>
<p>Barie et al studied the epidemiology of fever in 2419 patients admitted to their surgical ICU over a 14-month period.<sup><xref ref-type="bibr" rid="bibr4-0885066611402463">4</xref></sup> Fever was present in 626 patients (26%). Febrile patients had an increased ICU length of stay (LOS) and overall mortality (26.5% vs 6.5%, <italic>P</italic> &lt; .0001). Infections were responsible for 46% of febrile episodes. Many patients had a primary neurologic diagnosis. Therefore, neurogenic fever was the most common cause of noninfectious fever. After exclusion of neurologic patients, logistic regression analysis revealed that in addition to APACHE III scores, peak temperature was the most powerful predictor of mortality (odds ratio [OR] 1.84 for each 1° increase in temperature, 95% confidence interval [CI] 1.23-2.75).</p>
<p>The largest study looking at the epidemiology of fever in general medical and surgical ICU patients is that of Laupland et al.<sup><xref ref-type="bibr" rid="bibr15-0885066611402463">15</xref></sup> They studied fever in 20 466 critically ill adults with a broad range of admission diagnoses from 2000 to 2006. The cumulative incidences of fever and high fever were 44% and 8%, respectively. Positive cultures were associated with 17% and 31% of fever and high-fever episodes, respectively. This study did not find that the presence of fever (on its own) was associated with a crude increased risk of death. Rather, the presence of high fever was associated with a significantly increased risk of death (20.3% vs 12%, <italic>P</italic> &lt; .0001). Compared to medical patients who did not develop a fever during ICU admission, medical patients who were either afebrile or febrile at ICU admission and subsequently went on to develop high fever were at adjusted odds ratios of 1.91 (1.36-2.70) and 1.29 (0.85-1.96) for death, respectively.</p>
<p>The available literature with regard to the epidemiology of fever generally supports the fact that the presence of fever in critically ill patients may be associated with an increase in mortality. The earlier studies by Circiumaru<sup><xref ref-type="bibr" rid="bibr6-0885066611402463">6</xref></sup> and Peres Bota<sup><xref ref-type="bibr" rid="bibr44-0885066611402463">44</xref></sup> did not adjust their mortality estimates for illness severity and thus it was unclear if the presence of fever was simply reflective of the disease grade. However, the most recent, larger studies by Barie<sup><xref ref-type="bibr" rid="bibr4-0885066611402463">4</xref></sup> and Laupland<sup><xref ref-type="bibr" rid="bibr12-0885066611402463">12</xref></sup> found an association between death and fever or high fever, respectively, even after adjusting for illness severity. Given this association with increased chance for death, it is not unreasonable to assume that the treatment of fever with various antipyretic measures may improve patient outcomes. As illustrated in the next section, this assumption may not be as straightforward as it seems.</p>
</sec>
<sec id="section8-0885066611402463">
<title>Management of Fever</title>
<p>As the presence of fever may be associated with worse outcomes in neurologically intact ICU patients, a review of the evidence in support of different temperature management strategies is important. Unfortunately, there is a paucity of evidence in this area and strong arguments exist to justify treating and not-treating elevated body temperatures. Studies arguing against treating fever episodes have shown that naturally hypothermic septic patients are at higher risk for death than patients who are able to generate a fever.<sup><xref ref-type="bibr" rid="bibr6-0885066611402463">6</xref>,<xref ref-type="bibr" rid="bibr44-0885066611402463">44</xref><xref ref-type="bibr" rid="bibr45-0885066611402463"/>–<xref ref-type="bibr" rid="bibr46-0885066611402463">46</xref></sup> In addition, commonly employed antipyretics (nonsteroidal anti-inflammatories [NSAIDs], and/or acetaminophen) are associated with a not insignificant risk of bleeding and hepatic and renal toxicity.<sup><xref ref-type="bibr" rid="bibr47-0885066611402463">47</xref></sup> Other methods used to reduce temperature such as cooling blankets, ice packs, and intravascular cooling devices may produce shivering with an increase in metabolic demand and cause patient discomfort. Treatment of fever may also mask the presentation and diagnosis of severe underlying infections. This in turn may delay the administration of appropriate antimicrobial therapy which is clearly associated with increased mortality.<sup><xref ref-type="bibr" rid="bibr48-0885066611402463">48</xref>,<xref ref-type="bibr" rid="bibr49-0885066611402463">49</xref></sup> In vitro data have also shown a general trend toward lowering of the minimum inhibitory concentration of antimicrobials when tested at higher physiologic temperatures.<sup><xref ref-type="bibr" rid="bibr50-0885066611402463">50</xref></sup>
</p>
<p>On the other hand, temperatures sustained at extremely high levels (&gt;40°C) may worsen cerebral edema and precipitate multisystem organ failure.<sup><xref ref-type="bibr" rid="bibr51-0885066611402463">51</xref></sup> It is generally accepted that these extreme temperatures be lowered using pharmacologic and/or external cooling methods. However, there is no consensus opinion with regard to the management of patients whose temperature is between 38.3°C and 40.0°C. Arguments in support of treating this mild temperature elevation include an improvement in patient comfort and a reduction in metabolic demands. This is especially true for patients with refractory shock or acute myocardial infarction wherein a decrease in core temperature may result in a dramatic improvement in physiology. The presence of fever generally prompts additional investigations and antimicrobial therapy.<sup><xref ref-type="bibr" rid="bibr52-0885066611402463">52</xref></sup> Proponents of treating fever consequently argue that the treatment of fever will reduce hospitalization costs via a reduction in excessive investigation and overuse of antimicrobial therapy, but this argument is not supported by any robust data.</p>
<p>There are relatively few randomized trials that assess the effects of antipyretic therapy on critically ill adults without acute neurological injury. With the exception of 1 trial,<sup><xref ref-type="bibr" rid="bibr53-0885066611402463">53</xref></sup> most of these studies are limited by small sample size<sup><xref ref-type="bibr" rid="bibr7-0885066611402463">7</xref>,<xref ref-type="bibr" rid="bibr54-0885066611402463">54</xref><xref ref-type="bibr" rid="bibr55-0885066611402463"/>–<xref ref-type="bibr" rid="bibr56-0885066611402463">56</xref></sup> or an inability to perform a true randomization of interventions.<sup><xref ref-type="bibr" rid="bibr55-0885066611402463">55</xref></sup> A summary of the largest truly randomized studies is presented in <xref ref-type="table" rid="table3-0885066611402463">Table 3</xref>
. Bernard et al conducted a multicenter, randomized, placebo-controlled trial in 455 septic patients with fever or hypothermia and at least 1 organ failure.<sup><xref ref-type="bibr" rid="bibr53-0885066611402463">53</xref></sup> Patients were randomized to receive 10 mg/kg of ibuprofen every 6 hours for 8 doses or placebo. Most patients had a medical admission diagnosis and the most common sites of infection were lung (47%), peritoneum (15%), urinary tract (10%), and other/unknown (27%). In spite of the fact that temperature, heart rate, and oxygen consumption were decreased in the ibuprofen group, there was no difference in the primary outcome of 30-day mortality (37% for ibuprofen vs 40% for placebo). The results of this study are mitigated by the fact that the rates of acetaminophen use increased and decreased in the placebo and ibuprofen groups, respectively, during the study. This differential cointervention with acetaminophen (a known antipyretic) introduced a bias that minimized any potential difference between the treatment and the placebo groups.</p>
<table-wrap id="table3-0885066611402463" position="float">
<label>Table 3.</label>
<caption>
<p>Summary of Randomized Clinical Trials Investigating the Management of Fever in the Critically Ill</p>
</caption>
<graphic alternate-form-of="table3-0885066611402463" xlink:href="10.1177_0885066611402463-table3.tif"/>
<table>
<thead>
<tr>
<th>Reference</th>
<th>Study Population</th>
<th>Fever Definition (°C)</th>
<th>Intervention</th>
<th>Findings</th>
<th>Limitations</th>
</tr>
</thead>
<tbody>
<tr>
<td>Bernard et al.<sup><xref ref-type="bibr" rid="bibr60-0885066611402463">60</xref></sup>
</td>
<td>455 septic patients with fever or hypothermia and ≥ 1 organ failure</td>
<td>≥38.3</td>
<td>10 mg/kg ibuprofen q6h × 8 doses or placebo</td>
<td>No difference in 30-day mortality</td>
<td>Significant differential cointervention with acetaminophen</td>
</tr>
<tr>
<td>Gozzoli et al<sup><xref ref-type="bibr" rid="bibr54-0885066611402463">54</xref></sup>
</td>
<td>38 febrile surgical patients with SIRS<sup><xref ref-type="table-fn" rid="table-fn5-0885066611402463">a</xref></sup>
</td>
<td>≥38.5</td>
<td>External cooling vs no intervention</td>
<td>No significant difference in outcomes</td>
<td>Underpowered study</td>
</tr>
<tr>
<td>Schulman et al<sup><xref ref-type="bibr" rid="bibr7-0885066611402463">7</xref></sup>
</td>
<td>82 febrile trauma or surgical ICU patients</td>
<td>&gt;38.5</td>
<td>Aggressive vs permissive fever management<sup><xref ref-type="table-fn" rid="table-fn6-0885066611402463">b</xref></sup>
</td>
<td>Increased deaths in aggressive group</td>
<td>Underpowered; no description of problems with shivering, analgesia, etc</td>
</tr>
<tr>
<td>Morris et al<sup><xref ref-type="bibr" rid="bibr56-0885066611402463">56</xref></sup>
</td>
<td>120 febrile patients (53 were critically ill)</td>
<td>&gt;38.3</td>
<td>Ibuprofen (100, 200, or 400 mg) vs placebo</td>
<td>400 mg ibuprofen is most effective in lowering temperature</td>
<td>Small group of critically ill patients</td>
</tr>
</tbody>
</table>
<table-wrap-foot>
<fn id="table-fn5-0885066611402463">
<p>
<sup>a</sup>Aggressive treatment = acetaminophen 650 mg q6h for temperature of &gt;38.5°C and cooling blanket added for temperature of &gt;39.5°C; Permissive group = acetaminophen 650 mg q6h and cooling blanket for temperature of &gt;40°C.</p></fn>
<fn id="table-fn6-0885066611402463">
<p>
<sup>b</sup>SIRS, systemic inflammatory response syndrome.</p>
</fn>
</table-wrap-foot>
</table-wrap>
<p>Gozzoli et al studied the effects of external cooling on outcomes in 38 febrile patients with systemic inflammatory response syndrome (SIRS) admitted to their surgical ICU.<sup><xref ref-type="bibr" rid="bibr54-0885066611402463">54</xref></sup> In all, 18 patients received external cooling for a temperature of ≥38.5°C with cooling blankets, ice packs, and cloths and 20 patients received no antipyretic therapy. A total of 50% of each of the intervention and control group had a known focus of infection. This underpowered study found that temperature decreased similarly in both groups and there was no significant difference in fever recurrence, infection incidence, antibiotherapy, ICU or hospital LOS, or mortality.</p>
<p>Another study investigating the effects of a temperature-lowering strategy on critically ill adults is that of Schulman et al.<sup><xref ref-type="bibr" rid="bibr7-0885066611402463">7</xref></sup> These authors conducted an open, randomized trial comparing the effects of an aggressive versus a permissive fever management strategy in 82 patients admitted to a surgical ICU. The aggressive treatment group received acetaminophen 650 mg every 6 hours when their temperature was above 38.5°C. This was continued until fever resolution and a cooling blanket was added if temperature exceeded 39.5°C. The permissive treatment group did not receive treatment until their temperature exceeded 40.0°C at which point this group received the aggressive treatment protocol including the cooling blanket. Although this study was not powered to detect the differences in mortality, there was a trend toward an increased number of deaths in the aggressive group (7 vs 1 in the permissive group, <italic>P</italic> = .06). This finding resulted in the study being stopped early, which precluded the detection of a difference in the primary endpoint of infection development. On further review, there were a number of flaws with this study. First, the authors only included patients admitted to ICU for at least 72 hours, which may have selected for patients with nosocomial illnesses such as nosocomial pneumonia, bloodstream infection, etc. In addition, patients had a median of 3 to 4 infections over an average 3-week ICU stay, which seems unusually high. Furthermore, the authors do not report the proportion of patients who experienced cooling blanket intolerances and how this was managed, that is, use of sedatives, neuromuscular blockers, or meperidine. An increased use of these drugs may help to explain the increased mortality observed in the aggressive fever treatment group. Finally, this study was not designed to detect a difference in mortality and this unexpected finding needs to be confirmed in a larger trial.</p>
<p>Morris et al recently published a multicenter study wherein they randomized 120 febrile (temperature &gt;38.3°C) adults (53/120 were critically ill) to receive intravenous ibuprofen (100, 200, or 400 mg) or placebo every 4 hours for a total of 6 doses.<sup><xref ref-type="bibr" rid="bibr56-0885066611402463">56</xref></sup> The primary endpoint was the proportion of patients afebrile at 4 hours after study drug administration. For the overall study population, the difference in the primary endpoint was most significant when comparing the group treated with 400 mg of ibuprofen to placebo (77% vs 32% respectively, <italic>P</italic> = .0005). Upon inspecting the data provided in their figures, this difference appears significant for the population of critically ill patients; however, the exact data are not provided by the authors. No significant difference was noted in the rate of serious adverse events including renal failure, bleeding, and mortality.</p>
<p>Although strong arguments exist for and against the treatment of fever, the currently available randomized trial literature does not support an outcome benefit from a particular fever management strategy. As such, treatment of fever is inconsistent. This is supported by the results of a retrospective audit of antipyretic prescribing practice by Isaacs et al.<sup><xref ref-type="bibr" rid="bibr5-0885066611402463">5</xref></sup> They found that 50% of the study population received an antipyretic order and 86% of antipyretic orders were written to be given “as needed” at the discretion of the bedside nurse. Although this study is nearly 20 years old, the lack of data guiding fever management indicates that inconsistencies in fever management are likely the standard of care.</p>
<p>Future studies should focus on the biological response (cytokines, heat shock proteins, etc) to temperature control strategies in patients with fever. This would lead to an improved pathophysiologic understanding of fever induction, which in turn would help clinicians to understand the reason for a particular temperature control strategy. This improved understanding may lead to a more consistent approach to fever management in the ICU and a possible reduction in morbidity and mortality for critically ill patients presenting with this common symptom.</p>
</sec>
<sec id="section9-0885066611402463">
<title>Conclusions</title>
<p>Fever is a common physiologic abnormality detected in critically ill adults and its acquisition in ICU is associated with worse patient outcomes. Although a number of studies have investigated the pathophysiology of fever, there is still uncertainty with regard to the nature of the interaction of many of the inflammatory markers detected during a febrile episode. There is also a paucity of randomized trial data to guide fever management in neurologically intact critically ill adults. Large, multicenter, randomized trials are needed to guide the creation of protocols for the understanding and management of fever in critically ill adults.</p>
</sec>
</body>
<back>
<fn-group>
<fn fn-type="conflict" id="fn1-0885066611402463">
<label>Declaration of Conflicting Interests</label>
<p>The author(s) declared no conflicts of interest with respect to the authorship and/or publication of this article.</p>
</fn>
<fn fn-type="financial-disclosure" id="fn2-0885066611402463">
<label>Funding</label>
<p>The author(s) received no financial support for the research and/or authorship of this article.</p>
</fn>
</fn-group>
<ref-list>
<title>References</title>
<ref id="bibr1-0885066611402463">
<label>1</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Laupland</surname>
<given-names>KB</given-names>
</name>
<name>
<surname>Shahpori</surname>
<given-names>R</given-names>
</name>
<name>
<surname>Kirkpatrick</surname>
<given-names>AW</given-names>
</name>
<name>
<surname>Ross</surname>
<given-names>T</given-names>
</name>
<name>
<surname>Gregson</surname>
<given-names>DB</given-names>
</name>
<name>
<surname>Stelfox</surname>
<given-names>HT</given-names>
</name>
</person-group>. <article-title>Occurrence and outcome of fever in critically ill adults</article-title>. <source>Crit Care Med</source>. <year>2008</year>;<volume>36</volume>(<issue>5</issue>):<fpage>1531</fpage>–<lpage>1535</lpage>.</citation>
</ref>
<ref id="bibr2-0885066611402463">
<label>2</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Ryan</surname>
<given-names>M</given-names>
</name>
<name>
<surname>Levy</surname>
<given-names>MM</given-names>
</name>
</person-group>. <article-title>Clinical review: fever in intensive care unit patients</article-title>. <source>Crit Care (London, England)</source>. <year>2003</year>;<volume>7</volume>(<issue>3</issue>):<fpage>221</fpage>–<lpage>225</lpage>.</citation>
</ref>
<ref id="bibr3-0885066611402463">
<label>3</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>O’Grady</surname>
<given-names>NP</given-names>
</name>
<name>
<surname>Barie</surname>
<given-names>PS</given-names>
</name>
<name>
<surname>Bartlett</surname>
<given-names>JG</given-names>
</name>
<etal/>
</person-group>. <article-title>Guidelines for evaluation of new fever in critically ill adult patients: 2008 update from the American College of Critical Care Medicine and the Infectious Diseases Society of America</article-title>. <source>Crit Care Med</source>. <year>2008</year>;<volume>36</volume>(<issue>4</issue>):<fpage>1330</fpage>–<lpage>1349</lpage>.</citation>
</ref>
<ref id="bibr4-0885066611402463">
<label>4</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Barie</surname>
<given-names>PS</given-names>
</name>
<name>
<surname>Hydo</surname>
<given-names>LJ</given-names>
</name>
<name>
<surname>Eachempati</surname>
<given-names>SR</given-names>
</name>
</person-group>. <article-title>Causes and consequences of fever complicating critical surgical illness</article-title>. <source>Surg Infect</source>. <year>2004</year>;<volume>5</volume>(<issue>2</issue>):<fpage>145</fpage>–<lpage>159</lpage>.</citation>
</ref>
<ref id="bibr5-0885066611402463">
<label>5</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Isaacs</surname>
<given-names>SN</given-names>
</name>
<name>
<surname>Axelrod</surname>
<given-names>PI</given-names>
</name>
<name>
<surname>Lorber</surname>
<given-names>B</given-names>
</name>
</person-group>. <article-title>Antipyretic orders in a university hospital</article-title>. <source>Am J Med</source>. <year>1990</year>;<volume>88</volume>(<issue>1</issue>):<fpage>31</fpage>–<lpage>35</lpage>.</citation>
</ref>
<ref id="bibr6-0885066611402463">
<label>6</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Circiumaru</surname>
<given-names>B</given-names>
</name>
<name>
<surname>Baldock</surname>
<given-names>G</given-names>
</name>
<name>
<surname>Cohen</surname>
<given-names>J</given-names>
</name>
</person-group>. <article-title>A prospective study of fever in the intensive care unit</article-title>. <source>Intensive Care Med</source>. <year>1999</year>;<volume>25</volume>(<issue>7</issue>):<fpage>668</fpage>–<lpage>673</lpage>.</citation>
</ref>
<ref id="bibr7-0885066611402463">
<label>7</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Schulman</surname>
<given-names>CI</given-names>
</name>
<name>
<surname>Namias</surname>
<given-names>N</given-names>
</name>
<name>
<surname>Doherty</surname>
<given-names>J</given-names>
</name>
<etal/>
</person-group>. <article-title>The effect of antipyretic therapy upon outcomes in critically ill patients: a randomized, prospective study</article-title>. <source>Surg Infect</source>. <year>2006</year>;<volume>6</volume>(<issue>4</issue>):<fpage>369</fpage>–<lpage>375</lpage>.</citation>
</ref>
<ref id="bibr8-0885066611402463">
<label>8</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Lefrant</surname>
<given-names>JY</given-names>
</name>
<name>
<surname>Muller</surname>
<given-names>L</given-names>
</name>
<name>
<surname>de La Coussaye</surname>
<given-names>JE</given-names>
</name>
<etal/>
</person-group>. <article-title>Temperature measurement in intensive care patients: comparison of urinary bladder, oesophageal, rectal, axillary, and inguinal methods versus pulmonary artery core method</article-title>. <source>Intensive Care Med</source>. <year>2003</year>;<volume>29</volume>(<issue>3</issue>):<fpage>414</fpage>–<lpage>418</lpage>.</citation>
</ref>
<ref id="bibr9-0885066611402463">
<label>9</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Hooper</surname>
<given-names>VD</given-names>
</name>
<name>
<surname>Andrews</surname>
<given-names>JO</given-names>
</name>
</person-group>. <article-title>Accuracy of noninvasive core temperature measurement in acutely ill adults: the state of the science</article-title>. <source>Biol Res Nurs</source>. <year>2006</year>;<volume>8</volume>(<issue>1</issue>):<fpage>24</fpage>–<lpage>34</lpage>.</citation>
</ref>
<ref id="bibr10-0885066611402463">
<label>10</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Bouchama</surname>
<given-names>A</given-names>
</name>
<name>
<surname>Knochel</surname>
<given-names>JP</given-names>
</name>
</person-group>. <article-title>Heat stroke</article-title>. <source>N Engl J Med</source>. <year>2002</year>;<volume>346</volume>(<issue>25</issue>):<fpage>1978</fpage>–<lpage>1988</lpage>.</citation>
</ref>
<ref id="bibr11-0885066611402463">
<label>11</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Denborough</surname>
<given-names>M</given-names>
</name>
</person-group>. <article-title>Malignant hyperthermia</article-title>. <source>Lancet</source>. <year>1998</year>;<volume>352</volume>(<issue>9134</issue>):<fpage>1131</fpage>–<lpage>1136</lpage>.</citation>
</ref>
<ref id="bibr12-0885066611402463">
<label>12</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Laupland</surname>
<given-names>KB</given-names>
</name>
</person-group>. <article-title>Fever in the critically ill medical patient</article-title>. <source>Critical Care Medicine</source>. <year>2009</year>;<volume>37</volume>(<issue>Suppl 7</issue>):<fpage>S273</fpage>–<lpage>278</lpage>.</citation>
</ref>
<ref id="bibr13-0885066611402463">
<label>13</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Vincent</surname>
<given-names>J-L</given-names>
</name>
</person-group>. <article-title>Nosocomial infections in adult intensive-care units</article-title>. <source>Lancet</source>. <year>2003</year>;<volume>361</volume>(<issue>9374</issue>):<fpage>2068</fpage>–<lpage>2077</lpage>.</citation>
</ref>
<ref id="bibr14-0885066611402463">
<label>14</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Bagshaw</surname>
<given-names>SM</given-names>
</name>
<name>
<surname>Laupland</surname>
<given-names>KB</given-names>
</name>
</person-group>. <article-title>Epidemiology of intensive care unit-acquired urinary tract infections</article-title>. <source>Curr Opin Infect Dis</source>. <year>2006</year>;<volume>19</volume>(<issue>1</issue>):<fpage>67</fpage>–<lpage>71</lpage>.</citation>
</ref>
<ref id="bibr15-0885066611402463">
<label>15</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Laupland</surname>
<given-names>KB</given-names>
</name>
<name>
<surname>Bagshaw</surname>
<given-names>SM</given-names>
</name>
<name>
<surname>Gregson</surname>
<given-names>DB</given-names>
</name>
<name>
<surname>Kirkpatrick</surname>
<given-names>AW</given-names>
</name>
<name>
<surname>Ross</surname>
<given-names>T</given-names>
</name>
<name>
<surname>Church</surname>
<given-names>DL</given-names>
</name>
</person-group>. <article-title>Intensive care unit-acquired urinary tract infections in a regional critical care system</article-title>. <source>Critical Care (London, England)</source>. <year>2005</year>;<volume>9</volume>(<issue>2</issue>):<fpage>R60</fpage>–<lpage>R65</lpage>.</citation>
</ref>
<ref id="bibr16-0885066611402463">
<label>16</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Laupland</surname>
<given-names>KB</given-names>
</name>
<name>
<surname>Gregson</surname>
<given-names>DB</given-names>
</name>
<name>
<surname>Zygun</surname>
<given-names>DA</given-names>
</name>
<name>
<surname>Doig</surname>
<given-names>CJ</given-names>
</name>
<name>
<surname>Mortis</surname>
<given-names>G</given-names>
</name>
<name>
<surname>Church</surname>
<given-names>DL</given-names>
</name>
</person-group>. <article-title>Severe bloodstream infections: a population-based assessment</article-title>. <source>Crit Care Med</source>. <year>2004</year>;<volume>32</volume>(<issue>4</issue>):<fpage>992</fpage>–<lpage>997</lpage>.</citation>
</ref>
<ref id="bibr17-0885066611402463">
<label>17</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Blatteis</surname>
<given-names>CM</given-names>
</name>
<name>
<surname>Li</surname>
<given-names>S</given-names>
</name>
<name>
<surname>Li</surname>
<given-names>Z</given-names>
</name>
<name>
<surname>Feleder</surname>
<given-names>C</given-names>
</name>
<name>
<surname>Perlik</surname>
<given-names>V</given-names>
</name>
</person-group>. <article-title>Cytokines, PGE2 and endotoxic fever: a re-assessment</article-title>. <source>Prostaglandins Other Lipid Mediat</source>. <year>2005</year>;<volume>76</volume>(<issue>1-4</issue>):<fpage>1</fpage>–<lpage>18</lpage>.</citation>
</ref>
<ref id="bibr18-0885066611402463">
<label>18</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Boulant</surname>
<given-names>JA</given-names>
</name>
</person-group>. <article-title>Role of the preoptic-anterior hypothalamus in thermoregulation and fever</article-title>. <source>Clin Infect Dis</source>. <year>2000</year>;<volume>31</volume>(<issue>Suppl 5</issue>):<fpage> S157</fpage>–<lpage>S161</lpage>.</citation>
</ref>
<ref id="bibr19-0885066611402463">
<label>19</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Jansky</surname>
<given-names>L</given-names>
</name>
<name>
<surname>Vybiral</surname>
<given-names>S</given-names>
</name>
<name>
<surname>Pospisilova</surname>
<given-names>D</given-names>
</name>
<etal/>
</person-group>. <article-title>Production of systemic and hypothalamic cytokines during the early phase of endotoxin fever</article-title>. <source>Neuroendocrinology</source>. <year>1995</year>;<volume>62</volume>(<issue>1</issue>):<fpage>55</fpage>–<lpage>61</lpage>.</citation>
</ref>
<ref id="bibr20-0885066611402463">
<label>20</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Sehic</surname>
<given-names>E</given-names>
</name>
<name>
<surname>Szekely</surname>
<given-names>M</given-names>
</name>
<name>
<surname>Ungar</surname>
<given-names>AL</given-names>
</name>
<name>
<surname>Oladehin</surname>
<given-names>A</given-names>
</name>
<name>
<surname>Blatteis</surname>
<given-names>CM</given-names>
</name>
</person-group>. <article-title>Hypothalamic prostaglandin E2 during lipopolysaccharide-induced fever in guinea pigs</article-title>. <source>Brain Res Bull</source>. <year>1996</year>;<volume>39</volume>(<issue>6</issue>):<fpage>391</fpage>–<lpage>399</lpage>.</citation>
</ref>
<ref id="bibr21-0885066611402463">
<label>21</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Inoue</surname>
<given-names>W</given-names>
</name>
<name>
<surname>Matsumura</surname>
<given-names>K</given-names>
</name>
<name>
<surname>Yamagata</surname>
<given-names>K</given-names>
</name>
<name>
<surname>Takemiya</surname>
<given-names>T</given-names>
</name>
<name>
<surname>Shiraki</surname>
<given-names>T</given-names>
</name>
<name>
<surname>Kobayashi</surname>
<given-names>S</given-names>
</name>
</person-group>. <article-title>Brain-specific endothelial induction of prostaglandin E(2) synthesis enzymes and its temporal relation to fever</article-title>. <source>Neurosci Res</source>. <year>2002</year>;<volume>44</volume>(<issue>1</issue>):<fpage>51</fpage>–<lpage>61</lpage>.</citation>
</ref>
<ref id="bibr22-0885066611402463">
<label>22</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Blatteis</surname>
<given-names>CM</given-names>
</name>
</person-group>. <article-title>The onset of fever: new insights into its mechanism</article-title>. <source>Prog Brain Res</source>. <year>2007</year>;<volume>162</volume>:<fpage>3</fpage>–<lpage>14</lpage>.</citation>
</ref>
<ref id="bibr23-0885066611402463">
<label>23</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Li</surname>
<given-names>Z</given-names>
</name>
<name>
<surname>Perlik</surname>
<given-names>V</given-names>
</name>
<name>
<surname>Feleder</surname>
<given-names>C</given-names>
</name>
<name>
<surname>Tang</surname>
<given-names>Y</given-names>
</name>
<name>
<surname>Blatteis</surname>
<given-names>CM</given-names>
</name>
</person-group>. <article-title>Kupffer cell-generated PGE2 triggers the febrile response of guinea pigs to intravenously injected LPS</article-title>. <source>Am J Physiol Regul Integr Comp Physiol</source>. <year>2006</year>;<volume>290</volume>(<issue>5</issue>):<fpage>R1262</fpage>–<lpage>R1270</lpage>.</citation>
</ref>
<ref id="bibr24-0885066611402463">
<label>24</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Blatteis</surname>
<given-names>CM</given-names>
</name>
<name>
<surname>Li</surname>
<given-names>S</given-names>
</name>
<name>
<surname>Li</surname>
<given-names>Z</given-names>
</name>
<name>
<surname>Perlik</surname>
<given-names>V</given-names>
</name>
<name>
<surname>Feleder</surname>
<given-names>C</given-names>
</name>
</person-group>. <article-title>Signaling the brain in systemic inflammation: the role of complement</article-title>. <source>Front Biosci</source>. <year>2004</year>;<volume>9</volume>:<fpage>915</fpage>–<lpage>931</lpage>.</citation>
</ref>
<ref id="bibr25-0885066611402463">
<label>25</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Sehic</surname>
<given-names>E</given-names>
</name>
<name>
<surname>Blatteis</surname>
<given-names>CM</given-names>
</name>
</person-group>. <article-title>Blockade of lipopolysaccharide-induced fever by subdiaphragmatic vagotomy in guinea pigs</article-title>. <source>Brain Res</source>. <year>1996</year>;<volume>726</volume>(<issue>1-2</issue>):<fpage>160</fpage>–<lpage>166</lpage>.</citation>
</ref>
<ref id="bibr26-0885066611402463">
<label>26</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Feleder</surname>
<given-names>C</given-names>
</name>
<name>
<surname>Perlik</surname>
<given-names>V</given-names>
</name>
<name>
<surname>Blatteis</surname>
<given-names>CM</given-names>
</name>
</person-group>. <article-title>Preoptic alpha 1- and alpha 2-noradrenergic agonists induce, respectively, PGE2-independent and PGE2-dependent hyperthermic responses in guinea pigs</article-title>. <source>Am J Physiol Regul Integr Comp Physiol</source>. <year>2004</year>;<volume>286</volume>(<issue>6</issue>):<fpage>R1156</fpage>–<lpage>1166</lpage>.</citation>
</ref>
<ref id="bibr27-0885066611402463">
<label>27</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Henker</surname>
<given-names>R</given-names>
</name>
<name>
<surname>Kramer</surname>
<given-names>D</given-names>
</name>
<name>
<surname>Rogers</surname>
<given-names>S</given-names>
</name>
</person-group>. <article-title>Fever</article-title>. <source>AACN Clin Issues</source>. <year>1997</year>;<volume>8</volume>(<issue>3</issue>):<fpage>351</fpage>–<lpage>367</lpage>; <comment>quiz 505-356</comment>.
</citation>
</ref>
<ref id="bibr28-0885066611402463">
<label>28</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Lucas</surname>
<given-names>R</given-names>
</name>
<name>
<surname>Warner</surname>
<given-names>TD</given-names>
</name>
<name>
<surname>Vojnovic</surname>
<given-names>I</given-names>
</name>
<name>
<surname>Mitchell</surname>
<given-names>JA</given-names>
</name>
</person-group>. <article-title>Cellular mechanisms of acetaminophen: role of cyclo-oxygenase</article-title>. <source>FASEB J</source>. <year>2005</year>;<volume>19</volume>(<issue>6</issue>):<fpage>635</fpage>–<lpage>637</lpage>.</citation>
</ref>
<ref id="bibr29-0885066611402463">
<label>29</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Roth</surname>
<given-names>J</given-names>
</name>
</person-group>. <article-title>Endogenous antipyretics</article-title>. <source>Clin Chim Acta</source>. <year>2006</year>;<volume>371</volume>(<issue>1-2</issue>):<fpage>13</fpage>–<lpage>24</lpage>.</citation>
</ref>
<ref id="bibr30-0885066611402463">
<label>30</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>De Bosscher</surname>
<given-names>K</given-names>
</name>
<name>
<surname>Vanden Berghe</surname>
<given-names>W</given-names>
</name>
<name>
<surname>Haegeman</surname>
<given-names>G</given-names>
</name>
</person-group>. <article-title>The interplay between the glucocorticoid receptor and nuclear factor-kappaB or activator protein-1: molecular mechanisms for gene repression</article-title>. <source>Endocr Rev</source>. <year>2003</year>;<volume>24</volume>(<issue>4</issue>):<fpage>488</fpage>–<lpage>522</lpage>.</citation>
</ref>
<ref id="bibr31-0885066611402463">
<label>31</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Luheshi</surname>
<given-names>G</given-names>
</name>
<name>
<surname>Miller</surname>
<given-names>AJ</given-names>
</name>
<name>
<surname>Brouwer</surname>
<given-names>S</given-names>
</name>
<name>
<surname>Dascombe</surname>
<given-names>MJ</given-names>
</name>
<name>
<surname>Rothwell</surname>
<given-names>NJ</given-names>
</name>
<name>
<surname>Hopkins</surname>
<given-names>SJ</given-names>
</name>
</person-group>. <article-title>Interleukin-1 receptor antagonist inhibits endotoxin fever and systemic interleukin-6 induction in the rat</article-title>. <source>Am J Physiol</source>. <year>1996</year>;<volume>270</volume>(<issue>1 Pt 1</issue>):<fpage>E91</fpage>–<lpage>E95</lpage>.</citation>
</ref>
<ref id="bibr32-0885066611402463">
<label>32</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Cartmell</surname>
<given-names>T</given-names>
</name>
<name>
<surname>Ball</surname>
<given-names>C</given-names>
</name>
<name>
<surname>Bristow</surname>
<given-names>AF</given-names>
</name>
<name>
<surname>Mitchell</surname>
<given-names>D</given-names>
</name>
<name>
<surname>Poole</surname>
<given-names>S</given-names>
</name>
</person-group>. <article-title>Endogenous interleukin-10 is required for the defervescence of fever evoked by local lipopolysaccharide-induced and Staphylococcus aureus-induced inflammation in rats</article-title>. <source>J Physiol</source>. <year>2003</year>;<volume>549</volume>(<issue>Pt 2</issue>):<fpage>653</fpage>–<lpage>664</lpage>.</citation>
</ref>
<ref id="bibr33-0885066611402463">
<label>33</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Roth</surname>
<given-names>J</given-names>
</name>
<name>
<surname>Martin</surname>
<given-names>D</given-names>
</name>
<name>
<surname>Storr</surname>
<given-names>B</given-names>
</name>
<name>
<surname>Zeisberger</surname>
<given-names>E</given-names>
</name>
</person-group>. <article-title>Neutralization of pyrogen-induced tumour necrosis factor by its type 1 soluble receptor in guinea-pigs: effects on fever and interleukin-6 release</article-title>. <source>J Physiol</source>. <year>1998</year>;<volume>509</volume>(<issue>Pt 1</issue>):<fpage>267</fpage>–<lpage>275</lpage>.</citation>
</ref>
<ref id="bibr34-0885066611402463">
<label>34</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Stojanov</surname>
<given-names>S</given-names>
</name>
<name>
<surname>McDermott</surname>
<given-names>MF</given-names>
</name>
</person-group>. <article-title>The tumour necrosis factor receptor-associated periodic syndrome: current concepts</article-title>. <source>Expert Rev Mol Med</source>. <year>2005</year>;<volume>7</volume>(<issue>22</issue>):<fpage>1</fpage>–<lpage>18</lpage>.</citation>
</ref>
<ref id="bibr35-0885066611402463">
<label>35</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Rose-John</surname>
<given-names>S</given-names>
</name>
<name>
<surname>Neurath</surname>
<given-names>MF</given-names>
</name>
</person-group>. <article-title>IL-6 trans-signaling: the heat is on</article-title>. <source>Immunity</source>. <year>2004</year>;<volume>20</volume>(<issue>1</issue>):<fpage>2</fpage>–<lpage>4</lpage>.</citation>
</ref>
<ref id="bibr36-0885066611402463">
<label>36</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Hasday</surname>
<given-names>JD</given-names>
</name>
<name>
<surname>Singh</surname>
<given-names>IS</given-names>
</name>
</person-group>. <article-title>Fever and the heat shock response: distinct, partially overlapping processes</article-title>. <source>Cell Stress Chaperones</source>. <year>2000</year>;<volume>5</volume>(<issue>5</issue>):<fpage>471</fpage>–<lpage>480</lpage>.</citation>
</ref>
<ref id="bibr37-0885066611402463">
<label>37</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Pavlik</surname>
<given-names>A</given-names>
</name>
<name>
<surname>Aneja</surname>
<given-names>IS</given-names>
</name>
<name>
<surname>Lexa</surname>
<given-names>J</given-names>
</name>
<name>
<surname>Al-Zoabi</surname>
<given-names>BA</given-names>
</name>
</person-group>. <article-title>Identification of cerebral neurons and glial cell types inducing heat shock protein Hsp70 following heat stress in the rat</article-title>. <source>Brain Res</source>. <year>2003</year>;<volume>973</volume>(<issue>2</issue>):<fpage>179</fpage>–<lpage>189</lpage>.</citation>
</ref>
<ref id="bibr38-0885066611402463">
<label>38</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Yang</surname>
<given-names>YL</given-names>
</name>
<name>
<surname>Lu</surname>
<given-names>KT</given-names>
</name>
<name>
<surname>Tsay</surname>
<given-names>HJ</given-names>
</name>
<name>
<surname>Lin</surname>
<given-names>CH</given-names>
</name>
<name>
<surname>Lin</surname>
<given-names>MT</given-names>
</name>
</person-group>. <article-title>Heat shock protein expression protects against death following exposure to heatstroke in rats</article-title>. <source>Neurosci Lett</source>. <year>1998</year>;<volume>252</volume>(<issue>1</issue>):<fpage>9</fpage>–<lpage>12</lpage>.</citation>
</ref>
<ref id="bibr39-0885066611402463">
<label>39</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Ryan</surname>
<given-names>AJ</given-names>
</name>
<name>
<surname>Flanagan</surname>
<given-names>SW</given-names>
</name>
<name>
<surname>Moseley</surname>
<given-names>PL</given-names>
</name>
<name>
<surname>Gisolfi</surname>
<given-names>CV</given-names>
</name>
</person-group>. <article-title>Acute heat stress protects rats against endotoxin shock</article-title>. <source>J Appl Physiol</source>. <year>1992</year>;<volume>73</volume>(<issue>4</issue>):<fpage>1517</fpage>–<lpage>1522</lpage>.</citation>
</ref>
<ref id="bibr40-0885066611402463">
<label>40</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Hotchkiss</surname>
<given-names>R</given-names>
</name>
<name>
<surname>Nunnally</surname>
<given-names>I</given-names>
</name>
<name>
<surname>Lindquist</surname>
<given-names>S</given-names>
</name>
<name>
<surname>Taulien</surname>
<given-names>J</given-names>
</name>
<name>
<surname>Perdrizet</surname>
<given-names>G</given-names>
</name>
<name>
<surname>Karl</surname>
<given-names>I</given-names>
</name>
</person-group>. <article-title>Hyperthermia protects mice against the lethal effects of endotoxin</article-title>. <source>Am J Physiol</source>. <year>1993</year>;<volume>265</volume>(<issue>6 Pt 2</issue>):<fpage>R1447</fpage>–<lpage>R1457</lpage>.</citation>
</ref>
<ref id="bibr41-0885066611402463">
<label>41</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Cahill</surname>
<given-names>CM</given-names>
</name>
<name>
<surname>Waterman</surname>
<given-names>WR</given-names>
</name>
<name>
<surname>Xie</surname>
<given-names>Y</given-names>
</name>
<name>
<surname>Auron</surname>
<given-names>PE</given-names>
</name>
<name>
<surname>Calderwood</surname>
<given-names>SK</given-names>
</name>
</person-group>. <article-title>Transcriptional repression of the prointerleukin 1beta gene by heat shock factor 1</article-title>. <source>J Biol Chem</source>. <year>1996</year>;<volume>271</volume>(<issue>40</issue>):<fpage>24874</fpage>–<lpage>24879</lpage>.</citation>
</ref>
<ref id="bibr42-0885066611402463">
<label>42</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Sun</surname>
<given-names>D</given-names>
</name>
<name>
<surname>Chen</surname>
<given-names>D</given-names>
</name>
<name>
<surname>Du</surname>
<given-names>B</given-names>
</name>
<name>
<surname>Pan</surname>
<given-names>J</given-names>
</name>
</person-group>. <article-title>Heat shock response inhibits NF-kappaB activation and cytokine production in murine Kupffer cells</article-title>. <source>J Surg Res</source>. <year>2005</year>;<volume>129</volume>(<issue>1</issue>):<fpage>114</fpage>–<lpage>121</lpage>.</citation>
</ref>
<ref id="bibr43-0885066611402463">
<label>43</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Su</surname>
<given-names>F</given-names>
</name>
<name>
<surname>Nguyen</surname>
<given-names>ND</given-names>
</name>
<name>
<surname>Wang</surname>
<given-names>Z</given-names>
</name>
<name>
<surname>Cai</surname>
<given-names>Y</given-names>
</name>
<name>
<surname>Rogiers</surname>
<given-names>P</given-names>
</name>
<name>
<surname>Vincent</surname>
<given-names>JL</given-names>
</name>
</person-group>. <article-title>Fever control in septic shock: beneficial or harmful?</article-title>. <source>Shock</source>. <year>2005</year>;<volume>23</volume>(<issue>6</issue>):<fpage>516</fpage>–<lpage>520</lpage>.</citation>
</ref>
<ref id="bibr44-0885066611402463">
<label>44</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Peres Bota</surname>
<given-names>D</given-names>
</name>
<name>
<surname>Lopes Ferreira</surname>
<given-names>F</given-names>
</name>
<name>
<surname>Mélot</surname>
<given-names>C</given-names>
</name>
<name>
<surname>Vincent</surname>
<given-names>JL</given-names>
</name>
</person-group>. <article-title>Body temperature alterations in the critically ill</article-title>. <source>Intensive Care Med</source>. <year>2004</year>;<volume>30</volume>(<issue>5</issue>):<fpage>811</fpage>–<lpage>816</lpage>.</citation>
</ref>
<ref id="bibr45-0885066611402463">
<label>45</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Clemmer</surname>
<given-names>TP</given-names>
</name>
<name>
<surname>Fisher</surname>
<given-names>CJ</given-names>
</name>
<name>
<surname>Bone</surname>
<given-names>RC</given-names>
</name>
<name>
<surname>Slotman</surname>
<given-names>GJ</given-names>
</name>
<name>
<surname>Metz</surname>
<given-names>CA</given-names>
</name>
<name>
<surname>Thomas</surname>
<given-names>FO</given-names>
</name>
</person-group>. <article-title>Hypothermia in the sepsis syndrome and clinical outcome. The Methylprednisolone Severe Sepsis Study Group</article-title>. <source>Crit Care Med</source>. <year>1992</year>;<volume>20</volume>(<issue>10</issue>):<fpage>1395</fpage>–<lpage>1401</lpage>.</citation>
</ref>
<ref id="bibr46-0885066611402463">
<label>46</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Arons</surname>
<given-names>MM</given-names>
</name>
<name>
<surname>Wheeler</surname>
<given-names>AP</given-names>
</name>
<name>
<surname>Bernard</surname>
<given-names>GR</given-names>
</name>
<etal/>
</person-group>. <article-title>Effects of ibuprofen on the physiology and survival of hypothermic sepsis. Ibuprofen in Sepsis Study Group</article-title>. <source>Crit Care Med</source>. <year>1999</year>;<volume>27</volume>(<issue>4</issue>):<fpage>699</fpage>–<lpage>707</lpage>.</citation>
</ref>
<ref id="bibr47-0885066611402463">
<label>47</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Boyle</surname>
<given-names>M</given-names>
</name>
<name>
<surname>Hundy</surname>
<given-names>S</given-names>
</name>
<name>
<surname>Torda</surname>
<given-names>TA</given-names>
</name>
</person-group>. <article-title>Paracetamol administration is associated with hypotension in the critically ill</article-title>. <source>Aust Crit Care</source>. <year>1997</year>;<volume>10</volume>(<issue>4</issue>):<fpage>120</fpage>–<lpage>122</lpage>.</citation>
</ref>
<ref id="bibr48-0885066611402463">
<label>48</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Kumar</surname>
<given-names>A</given-names>
</name>
<name>
<surname>Roberts</surname>
<given-names>D</given-names>
</name>
<name>
<surname>Wood</surname>
<given-names>KE</given-names>
</name>
<etal/>
</person-group>. <article-title>Duration of hypotension before initiation of effective antimicrobial therapy is the critical determinant of survival in human septic shock</article-title>. <source>Crit Care Med</source>. <year>2006</year>;<volume>34</volume>(<issue>6</issue>):<fpage>1589</fpage>–<lpage>1596</lpage>.</citation>
</ref>
<ref id="bibr49-0885066611402463">
<label>49</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Manthous</surname>
<given-names>CA</given-names>
</name>
<name>
<surname>Hall</surname>
<given-names>JB</given-names>
</name>
<name>
<surname>Olson</surname>
<given-names>D</given-names>
</name>
<etal/>
</person-group>. <article-title>Effect of cooling on oxygen consumption in febrile critically ill patients</article-title>. <source>Am J Respir Crit Care Med</source>. <year>1995</year>;<volume>151</volume>(<issue>1</issue>):<fpage>10</fpage>–<lpage>14</lpage>.</citation>
</ref>
<ref id="bibr50-0885066611402463">
<label>50</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Mackowiak</surname>
<given-names>PA</given-names>
</name>
<name>
<surname>Marling-Cason</surname>
<given-names>M</given-names>
</name>
<name>
<surname>Cohen</surname>
<given-names>RL</given-names>
</name>
</person-group>. <article-title>Effects of temperature on antimicrobial susceptibility of bacteria</article-title>. <source>J Infect Dis</source>. <year>1982</year>;<volume>145</volume>(<issue>4</issue>):<fpage>550</fpage>–<lpage>553</lpage>.</citation>
</ref>
<ref id="bibr51-0885066611402463">
<label>51</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Cremer</surname>
<given-names>OL</given-names>
</name>
<name>
<surname>Kalkman</surname>
<given-names>CJ</given-names>
</name>
</person-group>. <article-title>Cerebral pathophysiology and clinical neurology of hyperthermia in humans</article-title>. <source>Prog Brain Res</source>. <year>2007</year>;<volume>162</volume>:<fpage>153</fpage>–<lpage>169</lpage>.</citation>
</ref>
<ref id="bibr52-0885066611402463">
<label>52</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Marik</surname>
<given-names>PE</given-names>
</name>
</person-group>. <article-title>Fever in the ICU</article-title>. <source>Chest</source>. <year>2000</year>;<volume>117</volume>(<issue>3</issue>):<fpage>855</fpage>–<lpage>869</lpage>.</citation>
</ref>
<ref id="bibr53-0885066611402463">
<label>53</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Bernard</surname>
<given-names>GR</given-names>
</name>
<name>
<surname>Wheeler</surname>
<given-names>AP</given-names>
</name>
<name>
<surname>Russell</surname>
<given-names>JA</given-names>
</name>
<etal/>
</person-group>. <article-title>The effects of ibuprofen on the physiology and survival of patients with sepsis. The Ibuprofen in Sepsis Study Group</article-title>. <source>N Engl J Med</source>. <year>1997</year>;<volume>336</volume>(<issue>13</issue>):<fpage>912</fpage>–<lpage>918</lpage>.</citation>
</ref>
<ref id="bibr54-0885066611402463">
<label>54</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Gozzoli</surname>
<given-names>V</given-names>
</name>
<name>
<surname>Schöttker</surname>
<given-names>P</given-names>
</name>
<name>
<surname>Suter</surname>
<given-names>PM</given-names>
</name>
<name>
<surname>Ricou</surname>
<given-names>B</given-names>
</name>
</person-group>. <article-title>Is it worth treating fever in intensive care unit patients? Preliminary results from a randomized trial of the effect of external cooling</article-title>. <source>Arch Intern Med</source>. <year>2001</year>;<volume>161</volume>(<issue>1</issue>):<fpage>121</fpage>–<lpage>123</lpage>.</citation>
</ref>
<ref id="bibr55-0885066611402463">
<label>55</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Henker</surname>
<given-names>R</given-names>
</name>
<name>
<surname>Rogers</surname>
<given-names>S</given-names>
</name>
<name>
<surname>Kramer</surname>
<given-names>DJ</given-names>
</name>
<name>
<surname>Kelso</surname>
<given-names>L</given-names>
</name>
<name>
<surname>Kerr</surname>
<given-names>M</given-names>
</name>
<name>
<surname>Sereika</surname>
<given-names>S</given-names>
</name>
</person-group>. <article-title>Comparison of fever treatments in the critically ill: a pilot study</article-title>. <source>Am J Crit Care</source>. <year>2001</year>;<volume>10</volume>(<issue>4</issue>):<fpage>276</fpage>–<lpage>280</lpage>.</citation>
</ref>
<ref id="bibr56-0885066611402463">
<label>56</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Morris</surname>
<given-names>PE</given-names>
</name>
<name>
<surname>Promes</surname>
<given-names>JT</given-names>
</name>
<name>
<surname>Guntupalli</surname>
<given-names>KK</given-names>
</name>
<name>
<surname>Wright</surname>
<given-names>PE</given-names>
</name>
<name>
<surname>Arons</surname>
<given-names>MM</given-names>
</name>
</person-group>. <article-title>A multi-center, randomized, double-blind, parallel, placebo-controlled trial to evaluate the efficacy, safety, and pharmacokinetics of intravenous ibuprofen for the treatment of fever in critically ill and non-critically ill adults</article-title>. <source>Crit Care</source>. <year>2010</year>;<volume>14</volume>(<issue>3</issue>):<fpage>R125</fpage>.</citation>
</ref>
<ref id="bibr57-0885066611402463">
<label>57</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Dinarello</surname>
<given-names>CA</given-names>
</name>
</person-group>. <article-title>Cytokines as endogenous pyrogens</article-title>. <source>J Infect Dis</source>. <year>1999</year>;<volume>179</volume>(<issue>Suppl 2</issue>):<fpage>S294</fpage>–<lpage>S304</lpage>.</citation>
</ref>
<ref id="bibr58-0885066611402463">
<label>58</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Dinarello</surname>
<given-names>CA</given-names>
</name>
<name>
<surname>Cannon</surname>
<given-names>JG</given-names>
</name>
<name>
<surname>Wolff</surname>
<given-names>SM</given-names>
</name>
<etal/>
</person-group>. <article-title>Tumor necrosis factor (cachectin) is an endogenous pyrogen and induces production of interleukin 1</article-title>. <source>J Exp Med</source>. <year>1986</year>;<volume>163</volume>(<issue>6</issue>):<fpage>1433</fpage>–<lpage>1450</lpage>.</citation>
</ref>
<ref id="bibr59-0885066611402463">
<label>59</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Chai</surname>
<given-names>Z</given-names>
</name>
<name>
<surname>Gatti</surname>
<given-names>S</given-names>
</name>
<name>
<surname>Toniatti</surname>
<given-names>C</given-names>
</name>
<name>
<surname>Poli</surname>
<given-names>V</given-names>
</name>
<name>
<surname>Bartfai</surname>
<given-names>T</given-names>
</name>
</person-group>. <article-title>Interleukin (IL)-6 gene expression in the central nervous system is necessary for fever response to lipopolysaccharide or IL-1 beta: a study on IL-6-deficient mice</article-title>. <source>J Exp Med</source>. <year>1996</year>;<volume>183</volume>(<issue>1</issue>):<fpage>311</fpage>–<lpage>316</lpage>.</citation>
</ref>
<ref id="bibr60-0885066611402463">
<label>60</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Baracos</surname>
<given-names>VE</given-names>
</name>
<name>
<surname>Whitmore</surname>
<given-names>WT</given-names>
</name>
<name>
<surname>Gale</surname>
<given-names>R</given-names>
</name>
</person-group>. <article-title>The metabolic cost of fever</article-title>. <source>Can J Physiol Pharmacol</source>. <year>1987</year>;<volume>65</volume>(<issue>6</issue>):<fpage>1248</fpage>–<lpage>1254</lpage>.</citation>
</ref>
</ref-list>
</back>
</article>